Company Overview
Alector, Inc. operates as a clinical stage biotechnology company focused on developing novel therapies designed to counteract the progression of neurodegeneration within the United States market. The company functions within the broader Healthcare sector, specifically the Biotechnology industry, positioning it as a specialized entity dedicated to addressing prevalent neurodegenerative diseases through its investigational pipeline. The firm employs a workforce of 103 individuals to advance its research and development efforts, including projects involving Nivisnebart, an investigational human recombinant monoclonal antibody, and AL137. With a market capitalization of $239.49M and trailing twelve-month revenue of $21.05M, the company represents a mid-cap biotechnology asset that has not yet achieved commercial profitability at scale.
Financial Health
Alector, Inc. reported revenue of $21.05M over the trailing twelve months, yet it incurred a net income of $-142,928,992 and an EBITDA of $-147,367,008, revealing a significant cost structure where operating expenses far exceed generated sales. This gap between modest revenue and substantial net losses indicates that the company is in a heavy investment phase typical of clinical-stage biotechs, where research and development costs dominate the financial statement. The company maintains a cash balance of $256.02M against total debt of $36.23M, suggesting a robust liquidity position relative to its obligations, though the debt-to-equity ratio stands at 118.22, reflecting a highly leveraged capital structure by traditional metrics. Despite holding significant cash reserves, the free cash flow for the trailing twelve months was negative at $-114,339,128, which constrains immediate financial flexibility and necessitates continued capital raising or cash burn management. The margins presented further illustrate the financial reality of the business, with a gross margin of 0.0%, an operating margin of -587.5%, and a profit margin of 0.0%, all indicating that costs are not being covered by gross revenue in the current period. Liquidity is supported by a current ratio of 3.83, which indicates a strong ability to meet short-term liabilities with short-term assets. However, the return on equity is -181.6% and the return on assets is -25.1%, metrics that reveal management has not yet generated positive returns on the capital invested in the business due to the absence of net income.
Valuation Assessment
The valuation metrics for Alector, Inc. reflect its pre-profitability status, with a P/E ratio (TTM) listed as N/A and a forward P/E of -2.39, implying that earnings are currently negative and traditional price-to-earnings comparisons are not applicable in the standard sense. The price-to-book ratio is 7.81, indicating that the market values the company at a significant premium over its net book value, likely due to the potential value of its intellectual property and clinical pipeline rather than tangible assets. Additionally, the price-to-sales ratio is 11.38 and the EV/EBITDA is -0.13, suggesting that investors are pricing the stock based on revenue multiples and enterprise value relative to negative earnings, which is common for early-stage life science firms. The stock has exhibited significant volatility within its trading range, with a 52-week high of $3.40 and a 52-week low of $0.87. Relative to this range, the current price sits below the 52-week high, reflecting the uncertainty and risk associated with a company that has not yet generated commercial revenue from its primary therapeutic candidates. The beta is 0.55, which means the stock's price volatility is lower than the broader market average, suggesting it may be less sensitive to general market fluctuations compared to large-cap equities.
Growth & Income
Revenue growth year-over-year is -88.5%, while earnings growth year-over-year is N/A, indicating a contraction in sales rather than expansion and confirming that earnings are not growing faster than revenue because the company is not yet profitable. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders but instead retains all earnings to fund ongoing research and development activities. The absence of a dividend payout is consistent with the company's financial profile, where reinvesting limited cash flows into its pipeline is the primary strategy for potential future growth. Overall, the growth and income profile for Alector, Inc. is characterized by negative revenue growth and a lack of income distribution, reflecting the high-risk, high-reward nature of a clinical-stage biotechnology firm that relies entirely on the success of its future product launches to achieve financial sustainability.